Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
- PMID: 32661059
- PMCID: PMC7402632
- DOI: 10.1126/science.abc6027
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Abstract
Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor-κB and characterized by increased tumor necrosis factor-α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7402632/bin/369_718_F1.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7402632/bin/369_718_F2.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7402632/bin/369_718_F3.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7402632/bin/369_718_F4.gif)
Comment in
-
Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients.Signal Transduct Target Ther. 2020 Sep 14;5(1):198. doi: 10.1038/s41392-020-00306-4. Signal Transduct Target Ther. 2020. PMID: 32929061 Free PMC article. No abstract available.
Similar articles
-
Making a case for using γδ T cells against SARS-CoV-2.Crit Rev Microbiol. 2020 Nov;46(6):689-702. doi: 10.1080/1040841X.2020.1822279. Epub 2020 Oct 7. Crit Rev Microbiol. 2020. PMID: 33023358 Review.
-
Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.Front Immunol. 2020 Aug 7;11:1748. doi: 10.3389/fimmu.2020.01748. eCollection 2020. Front Immunol. 2020. PMID: 32849623 Free PMC article. Review.
-
Activation and evasion of type I interferon responses by SARS-CoV-2.Nat Commun. 2020 Jul 30;11(1):3810. doi: 10.1038/s41467-020-17665-9. Nat Commun. 2020. PMID: 32733001 Free PMC article.
-
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.JCI Insight. 2020 Sep 3;5(17):e140329. doi: 10.1172/jci.insight.140329. JCI Insight. 2020. PMID: 32687484 Free PMC article.
-
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19.Sci Immunol. 2020 Jul 10;5(49):eabd1554. doi: 10.1126/sciimmunol.abd1554. Sci Immunol. 2020. PMID: 32651212 Free PMC article.
Cited by
-
The role of the cGAS-STING signaling pathway in viral infections, inflammatory and autoimmune diseases.Acta Pharmacol Sin. 2024 Jun 1. doi: 10.1038/s41401-023-01185-5. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 38822084 Review.
-
Performance of the Roche Elecsys® IGRA SARS-CoV-2 test for the detection and quantification of virus-reactive T cells in COVID-19-vaccinated immunosuppressed patients and healthy subjects.Eur J Clin Microbiol Infect Dis. 2024 May 23. doi: 10.1007/s10096-024-04852-5. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38777919
-
The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond.Cell Mol Immunol. 2024 May 22. doi: 10.1038/s41423-024-01167-5. Online ahead of print. Cell Mol Immunol. 2024. PMID: 38777879 Review.
-
Whole blood transcriptome signature predicts severe forms of COVID-19: Results from the COVIDeF cohort study.Funct Integr Genomics. 2024 May 21;24(3):107. doi: 10.1007/s10142-024-01359-2. Funct Integr Genomics. 2024. PMID: 38772950 Free PMC article.
-
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.Infect Dis Ther. 2024 Jul;13(7):1575-1588. doi: 10.1007/s40121-024-00992-5. Epub 2024 May 21. Infect Dis Ther. 2024. PMID: 38771550 Free PMC article.
References
-
- Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D. S. C., Du B., Li L.-J., Zeng G., Yuen K.-Y., Chen R.-C., Tang C.-L., Wang T., Chen P.-Y., Xiang J., Li S.-Y., Wang J.-L., Liang Z.-J., Peng Y.-X., Wei L., Liu Y., Hu Y.-H., Peng P., Wang J.-M., Liu J.-Y., Chen Z., Li G., Zheng Z.-J., Qiu S.-Q., Luo J., Ye C.-J., Zhu S.-Y., Zhong N.-S., China Medical Treatment Expert Group for Covid-19 , Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020). 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
-
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
-
- Salje H., Tran Kiem C., Lefrancq N., Courtejoie N., Bosetti P., Paireau J., Andronico A., Hozé N., Richet J., Dubost C.-L., Le Strat Y., Lessler J., Levy-Bruhl D., Fontanet A., Opatowski L., Boelle P.-Y., Cauchemez S., Estimating the burden of SARS-CoV-2 in France. Science eabc3517 (2020). 10.1126/science.abc3517 - DOI - PubMed
-
- Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Zhang Y., Song J., Wang S., Chao Y., Yang Z., Xu J., Zhou X., Chen D., Xiong W., Xu L., Zhou F., Jiang J., Bai C., Zheng J., Song Y., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 10.1001/jamainternmed.2020.0994 (2020). 10.1001/jamainternmed.2020.0994 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases